Valiant Laboratories Past Earnings Performance
Past criteria checks 0/6
Valiant Laboratories's earnings have been declining at an average annual rate of -144%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 59.2% per year.
Key information
-144.0%
Earnings growth rate
-141.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -59.2% |
| Return on equity | -4.3% |
| Net Margin | -9.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Valiant Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,115 | -100 | 46 | 0 |
| 30 Jun 24 | 1,495 | -45 | 45 | 0 |
| 31 Mar 24 | 1,821 | 3 | 43 | 0 |
| 31 Dec 23 | 2,427 | 111 | 48 | 0 |
| 30 Sep 23 | 2,730 | 227 | 47 | 0 |
| 30 Jun 23 | 2,994 | 276 | 45 | 0 |
| 31 Mar 23 | 3,339 | 290 | 46 | 0 |
| 31 Mar 22 | 3,124 | 341 | 33 | 0 |
Quality Earnings: VALIANTLAB is currently unprofitable.
Growing Profit Margin: VALIANTLAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VALIANTLAB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare VALIANTLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VALIANTLAB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20%).
Return on Equity
High ROE: VALIANTLAB has a negative Return on Equity (-4.31%), as it is currently unprofitable.